Powder: -20°C for 3 years | In solvent: -80°C for 1 year
J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1.J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM.
Description | J22352 promotes HDAC6 degradation and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma cancers, and leading to the restoration of host antitumor activity by reducing the immunosuppressive activity of PD-L1.J22352 is a PROTAC (proteolysis-targeting chimeras)-like and highly selective HDAC6 inhibitor with an IC50 value of 4.7 nM. |
Targets&IC50 | HDAC6:4.7 nM |
In vitro | J22352 (10 μM; 24 hours) shows a dose-dependent decrease in HDAC6 protein abundance. J22352 (0.1-20 μM; 72 hours) decreases U87MG cell viability in a dose-dependent manner. |
In vivo | J22352 is well tolerated in mice.J22352 (10?mg/kg; given i.p. per day for 14 days in male nude mice) results in a >80% tumor growth inhibition (TGI) rate. |
Molecular Weight | 415.44 |
Formula | C24H21N3O4 |
CAS No. | 2252395-44-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (300.89 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
J22352 2252395-44-9 Apoptosis Proteases/Proteasome Caspase J-22352 J 22352 inhibitor inhibit